By Tracy Staton Merck’s ($MRK) Gardasil journey is becoming a saga, with twists and turns all over the place. When first approved, the vaccine against human papillomavirus was tagged as a no-brainer blockbuster. But uptake of the vaccine hit a snag; after about a third of eligible girls were vaccinated, sales growth stalled. The company’s […]